Cortés Castán, JavierCescon, D. W.Rugo, H. S.Im, S. A.Yuso, M. Md.Gallardo, C.Lipatov, O.Barrios, C. H.Pérez García, José ManuelSchmid, P.Et al.2022-06-292022-06-292021Cortés, J., Cescon, D. W., Rugo, H. S., Im, S.-A., Md Yusof, M., Gallardo, C., Lipatov, O., Barrios, C. H., Perez-Garcia, J., Iwata, H., Masuda, N., Torregroza Otero, M., Gokmen, E., Loi, S., Guo, Z., Zhou, X., Karantza, V., Pan, W., & Schmid, P. (2021). KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Annals of Oncology, 32, S1289–S1290. https://doi.org/10.1016/j.annonc.2021.08.20890923-75341569-8041http://hdl.handle.net/11268/11407engNeoplasias de la mama triple negativasQuimioterapiaPlacebosconference output10.1016/j.annonc.2021.08.2089open accessCáncerTratamiento médicoEfectos fisiológicos